This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sato, N. Articles by Goggins, M. Search for Related Content PubMed PubMed Citation Articles by Sato, N. Articles by Goggins, M.

Discovery of Novel Targets for Aberrant Methylation in Pancreatic Carcinoma Using High-Throughput Microarrays¹

Departments of Pathology [N. S., N. F., A. M., H. M., R. H. H., M. G.], Oncology [C. J. Y., R. H. H., M. G.], Surgery [C. J. Y., J. L. C.], and Medicine [M. G.], The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205-2196

To identify potential targets for aberrant methylation in pancreatic cancer, we analyzed global changes in gene expression profiles of four pancreatic cancer cell lines after treatment with the demethylating agent 5-aza-2'-deoxycytidine (5Aza-dC) and/or the histone deacetylase inhibitor trichostatin A. A substantial number of genes were induced 5-fold or greater by 5Aza-dC alone (631 transcripts), trichostatin A alone (1196 transcripts), and by treatment with both agents (857 transcripts). Four hundred and seventy-five genes were markedly (>5-fold) induced after 5Aza-dC treatment in pancreatic cancer cell lines but not in a nonneoplastic pancreatic epithelial cell line. The methylation status of 11 of these 475 genes was examined in a panel of 42 pancreatic cancers, and all 11 of these genes were aberrantly methylated in pancreatic cancer but rarely, if any, methylated in 10 normal pancreatic ductal epithelia. These genes include UCHL1 (methylated in 100% of 42 pancreatic cancers), NPTX2 (98%), SARP2 (95%), CLDN5 (93%), reprimo (86%), LHX1 (76%), WNT7A (71%), FOXE1 (69%), TJP2 (64%), CDH3 (19%), and ST14 (10%). Three of these 11 genes (NPTX2, SARP2, and CLDN5) were selected for further analysis in a larger panel of specimens, and aberrant methylation of at least one of these three genes was detectable in 100% of 43 primary pancreatic cancers and in 18 of 24 (75%) pancreatic juice samples obtained from patients with pancreatic cancer. Thus, a substantial number of genes are induced by 5Aza-dC treatment of pancreatic cancer cells, and many of them may represent novel targets for aberrant methylation in pancreatic carcinoma.

This article has been cited by other articles:

				H. Takeshima, S. Yamashita, T. Shimazu, T. Niwa, and T. Ushijima The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands Genome Res., November 1, 2009; 19(11): 1974 - 1982. [Abstract] [Full Text] [PDF]

				H. J. Jun, S. Woolfenden, S. Coven, K. Lane, R. Bronson, D. Housman, and A. Charest Epigenetic Regulation of c-ROS Receptor Tyrosine Kinase Expression in Malignant Gliomas Cancer Res., March 15, 2009; 69(6): 2180 - 2184. [Abstract] [Full Text] [PDF]

				K. Brune, S.-M. Hong, A. Li, S. Yachida, T. Abe, M. Griffith, D. Yang, N. Omura, J. Eshleman, M. Canto, et al. Genetic and Epigenetic Alterations of Familial Pancreatic Cancers Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3536 - 3542. [Abstract] [Full Text] [PDF]

				C. D E Margetts, M. Morris, D. Astuti, D. C Gentle, A. Cascon, F. E McRonald, D. Catchpoole, M. Robledo, H. P H Neumann, F. Latif, et al. Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma Endocr. Relat. Cancer, September 1, 2008; 15(3): 777 - 786. [Abstract] [Full Text] [PDF]

				Q. Li, L. Tang, P. C. Roberts, J. M. Kraniak, A. L. Fridman, O. I. Kulaeva, O. S. Tehrani, and M. A. Tainsky Interferon Regulatory Factors IRF5 and IRF7 Inhibit Growth and Induce Senescence in Immortal Li-Fraumeni Fibroblasts Mol. Cancer Res., May 1, 2008; 6(5): 770 - 784. [Abstract] [Full Text] [PDF]

				G. Feldmann and A. Maitra Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts J. Mol. Diagn., March 1, 2008; 10(2): 111 - 122. [Abstract] [Full Text] [PDF]

				J. Ying, H. Li, J. Yu, K. M. Ng, F. F. Poon, S. C. C. Wong, A. T.C. Chan, J. J.Y. Sung, and Q. Tao WNT5A Exhibits Tumor-Suppressive Activity through Antagonizing the Wnt/ -Catenin Signaling, and Is Frequently Methylated in Colorectal Cancer Clin. Cancer Res., January 1, 2008; 14(1): 55 - 61. [Abstract] [Full Text] [PDF]

				S. Milutinovic, A. C. D'Alessio, N. Detich, and M. Szyf Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes Carcinogenesis, March 1, 2007; 28(3): 560 - 571. [Abstract] [Full Text] [PDF]

				B. Seliger, A. Fedorushchenko, W. Brenner, A. Ackermann, D. Atkins, S. Hanash, and R. Lichtenfels Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration[?Q1: Running head: UCHL1, a Biomarker of RCC. Short title OK?Q1] Clin. Cancer Res., January 1, 2007; 13(1): 27 - 37. [Abstract] [Full Text] [PDF]

				J. P. Hamilton, F. Sato, Z. Jin, B. D. Greenwald, T. Ito, Y. Mori, B. C. Paun, T. Kan, Y. Cheng, S. Wang, et al. Reprimo Methylation Is a Potential Biomarker of Barrett's-Associated Esophageal Neoplastic Progression. Clin. Cancer Res., November 15, 2006; 12(22): 6637 - 6642. [Abstract] [Full Text] [PDF]

				H. Wehbe, R. Henson, F. Meng, J. Mize-Berge, and T. Patel Interleukin-6 Contributes to Growth in Cholangiocarcinoma Cells by Aberrant Promoter Methylation and Gene Expression Cancer Res., November 1, 2006; 66(21): 10517 - 10524. [Abstract] [Full Text] [PDF]

				G. Foltz, G.-Y. Ryu, J.-G. Yoon, T. Nelson, J. Fahey, A. Frakes, H. Lee, L. Field, K. Zander, Z. Sibenaller, et al. Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma. Cancer Res., July 1, 2006; 66(13): 6665 - 6674. [Abstract] [Full Text] [PDF]

				I. Ibanez de Caceres, E. Dulaimi, A. M. Hoffman, T. Al-Saleem, R. G. Uzzo, and P. Cairns Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res., May 15, 2006; 66(10): 5021 - 5028. [Abstract] [Full Text] [PDF]

				K. Yamashita, H. L. Park, M. S. Kim, M. Osada, Y. Tokumaru, H. Inoue, M. Mori, and D. Sidransky PGP9.5 Methylation in Diffuse-Type Gastric Cancer. Cancer Res., April 1, 2006; 66(7): 3921 - 3927. [Abstract] [Full Text] [PDF]

				H. Matsubayashi, M. Canto, N. Sato, A. Klein, T. Abe, K. Yamashita, C. J. Yeo, A. Kalloo, R. Hruban, and M. Goggins DNA Methylation Alterations in the Pancreatic Juice of Patients with Suspected Pancreatic Disease Cancer Res., January 15, 2006; 66(2): 1208 - 1217. [Abstract] [Full Text] [PDF]

				P. Sova, Q. Feng, G. Geiss, T. Wood, R. Strauss, V. Rudolf, A. Lieber, and N. Kiviat Discovery of Novel Methylation Biomarkers in Cervical Carcinoma by Global Demethylation and Microarray Analysis Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 114 - 123. [Abstract] [Full Text] [PDF]

				M. Gronborg, T. Z. Kristiansen, A. Iwahori, R. Chang, R. Reddy, N. Sato, H. Molina, O. N. Jensen, R. H. Hruban, M. G. Goggins, et al. Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach Mol. Cell. Proteomics, January 1, 2006; 5(1): 157 - 171. [Abstract] [Full Text] [PDF]

				M. Goggins Molecular Markers of Early Pancreatic Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4524 - 4531. [Abstract] [Full Text] [PDF]

				M. R. Morris, D. Gentle, M. Abdulrahman, E. N. Maina, K. Gupta, R. E. Banks, M. S. Wiesener, T. Kishida, M. Yao, B. Teh, et al. Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell Carcinoma Cancer Res., June 1, 2005; 65(11): 4598 - 4606. [Abstract] [Full Text] [PDF]

				D. L. Mandelker, K. Yamashita, Y. Tokumaru, K. Mimori, D. L. Howard, Y. Tanaka, A. L. Carvalho, W.-W. Jiang, H. L. Park, M. S. Kim, et al. PGP9.5 Promoter Methylation Is an Independent Prognostic Factor for Esophageal Squamous Cell Carcinoma Cancer Res., June 1, 2005; 65(11): 4963 - 4968. [Abstract] [Full Text] [PDF]

				R. A. Winn, L. Marek, S.-Y. Han, K. Rodriguez, N. Rodriguez, M. Hammond, M. Van Scoyk, H. Acosta, J. Mirus, N. Barry, et al. Restoration of Wnt-7a Expression Reverses Non-small Cell Lung Cancer Cellular Transformation through Frizzled-9-mediated Growth Inhibition and Promotion of Cell Differentiation J. Biol. Chem., May 20, 2005; 280(20): 19625 - 19634. [Abstract] [Full Text] [PDF]

				N. Takai, N. Kawamata, C. S. Walsh, S. Gery, J. C. Desmond, S. Whittaker, J. W. Said, L. M. Popoviciu, P. A. Jones, I. Miyakawa, et al. Discovery of Epigenetically Masked Tumor Suppressor Genes in Endometrial Cancer Mol. Cancer Res., May 1, 2005; 3(5): 261 - 269. [Abstract] [Full Text] [PDF]

				H. Matsubayashi, N. Sato, K. Brune, A. L. Blackford, R. H. Hruban, M. Canto, C. J. Yeo, and M. Goggins Age- and Disease-Related Methylation of Multiple Genes in Nonneoplastic Duodenum and in Duodenal Juice Clin. Cancer Res., January 15, 2005; 11(2): 573 - 583. [Abstract] [Full Text] [PDF]

				N. Sato, N. Maehara, and M. Goggins Gene Expression Profiling of Tumor-Stromal Interactions between Pancreatic Cancer Cells and Stromal Fibroblasts Cancer Res., October 1, 2004; 64(19): 6950 - 6956. [Abstract] [Full Text] [PDF]

				Y. Tokumaru, K. Yamashita, M. Osada, S. Nomoto, D.-I. Sun, Y. Xiao, M. O. Hoque, W. H. Westra, J. A. Califano, and D. Sidransky Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing Cancer Res., September 1, 2004; 64(17): 5982 - 5987. [Abstract] [Full Text] [PDF]

				J. Okami, D. M. Simeone, and C. D. Logsdon Silencing of the Hypoxia-Inducible Cell Death Protein BNIP3 in Pancreatic Cancer Cancer Res., August 1, 2004; 64(15): 5338 - 5346. [Abstract] [Full Text] [PDF]